EGFR and non-small cell lung carcinoma: With this background, this study aimed to describe the effectiveness of erlotinib and gefitinib during the first decade of their routine use for the treatment of advanced EGFR-mutant nonsquamous NSCLC in the entire cohort of patients treated in New Zealand.